Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs VICI Properties Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $376.41 (market cap $10.01B), while VICI Properties Inc trades at $23.72 (market cap $26.12B). The key difference: VICI Properties Inc is far larger — about 2.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and VICI Properties Inc pays a 7.76% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Bio-Rad Laboratories, Inc. Class A Common Stock for 58 Days and VICI Properties Inc for 40 Days on average.
| BIO | VICI | |
|---|---|---|
Market Cap | $10.01B | $26.12B |
Volume | 324,345 | 18,974,706 |
Sector | Health | Real Estate |
52-Week High | $390.34 | $32.91 |
52-Week Low | $241.71 | $23.72 |
Typical Hold Time | 58 Days | 40 Days |
Enterprise Value | $9.76B | $43.67B |
Dividend Yield | — | 7.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $376.41, down 0.69% on the day, with a bullish technical signal supported by moving averages. The company reported a strong turnaround in 2025 with net income of $759.9 million, reversing prior losses, though recent quarters show mixed earnings performance. Analyst consensus is positive with 57% buy ratings and a $350 price target, while institutional interest remains strong, as seen with California State Teachers Retirement System's $1.79 billion stake as of September 2026.
The outlook is cautiously optimistic, driven by margin expansion targets and steady revenue, but risks include high valuation (P/E of 46.58) and softness in Life Science demand. Upside potential hinges on achieving mid-teens operating margins, while investor sentiment is buoyed by management's participation in recent healthcare conferences.
VICI trades at $23.72, down 3.3% over 24 hours, reflecting recent bearish technical momentum despite strong fundamentals. The stock shows high profitability with a net income margin of 67.5% and a P/E ratio of 9.34, indicating potential undervaluation. Recent earnings were mixed, with a Q1 2026 beat but Q4 2025 and Q2 2026 misses. Analyst consensus remains strongly bullish with a $29.11 price target, though technical indicators signal near-term caution.
The outlook for VICI is positive based on solid cash flow growth and a high dividend yield, but risks include earnings volatility and tenant concentration in the gaming sector. The current price offers a compelling entry point for income-focused investors, supported by institutional buying interest and a lack of sell ratings from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
